期刊
ASIAN JOURNAL OF ANDROLOGY
卷 13, 期 1, 页码 53-58出版社
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.1038/aja.2010.63
关键词
gamete biomarker; male fertility; sperm biomarker; sperm dysfunction
资金
- The Wellcome Trust
- TENOVUS (Scotland)
- University of Dundee
- MRC
- NHS Tayside
- Scottish Enterprise
Sperm dysfunction is the single most common cause of infertility, yet what is remarkable is that, there is no drug a man can take or add to his spermatozoa in vitro to improve fertility. One reason for the lack of progress in this area is that our understanding of the cellular and molecular workings of the mature spermatazoon is limited. However, over the last few years there has been considerable progress in our knowledge base and in addressing new methods to diagnose sperm dysfunction. We review the current state of the field and provide insights for further development. We conclude that: (i) there is little to be gained from more studies identifying/categorizing various populations of men using a basic semen assessment, where an effort is required in making sure the analysis is performed in an appropriate high quality way; (ii) technological development is likely to bring the reality of sperm function testing closer to implementation into the clinical pathways. In doing this, these assays must be robust, cheap (or more appropriately termed cost effective), easy to use and clinically useful; and (iii) clinical necessity, e. g., the need to identify the highest quality spermatozoon for injection is driving basic research forward. This is an exciting time to be an andrologist and, likely, a fruitful one. Asian Journal of Andrology (2011) 13, 53-58; doi: 10.1038/aja.2010.63; published online 22 November 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据